Introduction
Antibiotics are chemicals derived from microorganisms that have the capacity, in dilute solutions, to kill other microorganisms (bacteria, virus, fungi, and parasite) or inhibit their growth. In this study, antibiotics refer to collective term for antibacterial, antiviral, and antiparasitic agents. In routine clinical practice, antibiotics are chiefly used to eliminate various pathogens (bacteria, viruses, and parasites). Many antibiotics were later found to have anti-inflammatory properties apart from their antimicrobial action. We have discussed anti-inflammatory and antiimmunomodulatory effects of various antibacterial and antiparasitic drugs. Antiviral and antifungal drugs are seldom used for their anti-inflammatory properties. Indian Journal of Dermatology 2016; 61 (5) Dapsone Dapsone (4,4'-diaminodiphenylsulfone) is an aniline derivative belonging to the group of synthetic sulfones. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Peak plasma concentration is reached within 2-8 h after administration. The mean half-life of elimination is about 20-30 h. It is metabolized in liver by two distinct routes, N-acetylation and N-hydroxylation. It has dual functions of both antimicrobial/ antiprotozoal effects and anti-inflammatory features similar to nonsteroidal anti-inflammatory drugs. Dapsone has been used as a treatment option in various dermatological conditions because of its anti-inflammatory effects [ Table 3 ].
Macrolides
Macrolides contain a macrocyclic lactone ring structure. These are of actinomycetes or semisynthetic derivatives of same bacteria. They are bacteriostatic antibacterial agents which bind irreversibly to the large (50S) ribosomal subunit of bacteria, thereby inhibiting RNA-dependent protein synthesis. However, there have been many dermatological uses of macrolides for their immunomodulatory action. Azithromycin (A), roxithromycin (R), erythromycin (E), and clarithromycin (C) are commonly used in dermatology practice for their immunomodulatory and anti-inflammatory potential [ Table 4 ].
Metronidazole
Metronidazole is a synthetic nitroimidazole antibacterial drug. It acts by DNA disruption and nucleic acid synthesis inhibition. It acts against anaerobic bacteria and protozoa. However, it has many actions other than its antibacterial action for which it is being used in different dermatological diseases [ Table 5 ].
Rifampicin
Rifampicin (R) is a semisynthetic derivative of rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei. It is a broad-spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as Mechanism of action for anti-inflammatory property Dose Acne [1] [2] [3] [4] [5] Modulates cytokine production in LPS-stimulated macrophages Decreases TNF-α and IL-1β concentrations and increases serum IL-6 concentrations [2] Topical clindamycin 1% BD Folliculitis decalvans [6] Suppresses the complement-derived chemotaxis of polymorphonuclear leukocytes in vitro, thereby reducing the potential for inflammation Oral clindamycin 300 mg BD plus rifampicin 300 BD for 10 weeks Fox-Fordyce disease [7, 8] Suppresses the complement-derived chemotaxis of polymorphonuclear leukocytes in vitro, thereby reducing the potential for inflammation Topical clindamycin 1% BD Hidradenitis suppurativa [9] Inhibits complement-derived chemotaxis of polymorphonuclear leukocytes in vitro and reduces inflammation Immunomodulatory-clindamycin might enhance the uptake of microorganisms by the phagocytic cells of the host [10] Clindamycin 300 mg BD PO+ Rifampicin 300 mg BD PO for 10 weeks Rosacea [11, 12] Modulates cytokine production in LPS-stimulated macrophages Decreases TNF-α and IL-1β concentrations and increases serum IL-6 concentrations [2] Topical clindamycin 1% 5% benzoyl peroxide/1% clindamycin gel PO: Peroral, IL: Interleukin, TNF-α: Tumor necrosis factor-alpha, LPS: Lipopolysaccharide, BD: Twice a day Up to 300 mg daily in equal doses PO Granulomatous cheilitis [13] Alters the function of monocytes and neutrophils (inhibits PMN motility and lymphocyte transformation) [14] 100-200 mg PO Granuloma faciale [15] Inhibits lymphocyte transformation 100 mg BID to TID Lupus miliaris disseminatus faciei [16] Antigranulomatous effects [16] 100 mg 3 times/week PO Pyoderma gangrenosum [17, 18] Alters the function of monocytes and neutrophils (inhibits PMN motility and lymphocyte transformation) [12] 50-300 mg PO PMN: Polymorphonuclear neutrophils, PO: Peroral, PGE: Prostaglandin E well as many Gram-negative microorganisms. However, it has other properties besides antimicrobial action for which it has been used in various dermatological conditions [ Table 6 ].
Tetracyclines
The tetracyclines are broad-spectrum antibiotics and comprise four main drugs (tetracycline [ 
Antimalarials
The parent molecule for the antimalarials is quinine. Among antimalarials, chloroquine (CQ) and hydroxychloroquine (HCQ) are used in various dermatological disorders. Both CQ and HCQ are alkylated 4-aminoquinolines. HCQ is a derivative of CQ and is nearly completely absorbed within 2-4 h of an oral dose and metabolized in liver by dealkylation. The drugs accumulate in thrombocytes, granulocytes, and erythrocytes; hence, their concentration in whole blood is 3-10 times higher than that of plasma. CQ has high affinity for melanin and gets accumulated in the eyes and the skin where the concentration is 100-200 times higher than that of plasma; in the epidermis, it is 3-7 times higher than that of the dermis. The maximum daily dosage is 3.5-4 mg/kg of body weight for CQ and 6-6.5 mg/kg body weight for HCQ. Various indications for antimalarials drug are shown in Table 8 . [19, 20] Anti-inflammatory Topical 100-200 mg/day Behcet's disease [21, 22] Inhibits neutrophil chemotaxis [23] [24] [25] [26] 100-150 mg daily Bullous pemphigoid [27, 28] Inhibition of neutrophil cytotoxicity and chemotaxis 50-200 mg daily PO Bullous systemic lupus erythematosus [29, 30] Antineutrophil action 100 mg/day PO Chronic bullous disease of childhood [31] Inhibits the adherence of neutrophils to basement membrane zone antibody [24] 25-75 mg daily Cicatricial pemphigoid [32] Antineutrophil action 125-150 mg daily Dermatitis herpetiformis [33, 34] Antineutrophil action Up to 100-300 mg daily EBA [35, 36] Antineutrophil action [23] [24] [25] 1-2 mg/kg/day Erythema elevatum diutinum [37, 38] Antineutrophil action 100 mg/day Hailey-Hailey disease [39] Anti-inflammatory inhibition of neutrophils through the suppression of the halide-myeloperoxidase system 100-200 mg/day IgA pemphigus [40] Antineutrophil action 100 mg/day Leukocytoclastic vasculitis [41] Antineutrophil action 100 mg/day Linear IgA dermatosis [42] Inhibits the adherence of neutrophils to basement membrane zone antibody [24] 25-100 mg/day Lichen planus [43] Anti-inflammatory inhibiting the release of inflammatory or chemotactic factors from mast cells
50-150 mg/day
Pemphigus vulgaris [32] Oral inhibition of eosinophilic peroxidase [44] 125-150 mg daily Pustular psoriasis [45] Anti-inflammatory suppression of leukocyte chemotaxis and cytotoxicity 100 mg/day Pyoderma gangrenosum [46] Inhibition of neutrophil chemotaxis and reduction of oxygen intermediates [23] [24] [25] [26] 
100-200 mg daily
Relapsing polychondritis [47, 48] Inhibit lysosomal enzyme activity 100 mg daily SCPD [49] Inhibition of neutrophil cytotoxicity, inhibition of neutrophil chemotaxis, and alteration of glycosaminoglycans diluting inflammatory mediators
50-200 mg daily
Urticarial vasculitis syndrome [50, 51] Antineutrophil action and inhibition of eosinophil peroxidase EBA: Epidermolysis bullosa acquisita, SCPD: Subcorneal pustular dermatosis, PO: Peroral [52] [53] [54] Inhibits IL-8, neutrophil chemotaxis [49] [50] [51] 500 mg thrice weekly consecutive days for 6 months Adult onset Still's disease [55, 56] C Anti-inflammatory and immunomodulatory [49] 500 mg BD Bullous pemphigoid [57] [58] [59] E Anti-inflammatory and immunomodulatory [49] 1000-3000 mg/day Confluent and reticulated papillomatosis [60] A, R, C, E Inhibits cytokines, such as TNF-α and IL-1α induced by staphylococcal enterotoxin B, which modulate epidermal keratinization, [55] inhibits lymphocytic activity, [61] immunomodulation of keratinocytes [62] A -500 mg/day R -300 mg/day C -500 mg/day E -1000 mg/day Gingival hyperplasia A Block cyclosporine A-induced cell proliferation and Type 1 collagen synthesis, [63] [64] [65] [66] activates MMP-2 level [59] [60] [61] Initial dose of 500 mg, followed by a daily dose of 250 mg for 4 days [61] Granulomatous cheilitis R Inhibits inflammatory cytokines Anti-inflammatory [66] 150 mg/day
Immune thrombocytopenic purpura [67, 68] E, C Immunomodulatory-eradication of bacteria or by modulation of the immune system involving the mucosa on which commensal bacteria reside [69] E -600 mg/day C -500 mg/day
Lupus miliaris disseminatus faciei [70] R Anti-inflammatory activity, [63] inhibition of expression of vascular endothelial growth factor [71] 300 mg daily Perioral dermatitis [72] A, E, C Inhibits pro-inflammatory cytokines [52] [53] [54] 500 mg OD for 7 days Pityriasis rosea [73] [74] [75] A, E Inhibits pro-inflammatory cytokines [70] E -250 mg/400 mg QID Pityriasis lichenoides [76, 77] A, E Inhibits lymphocytic activity [58] A -500 mg on day 1 and 250 mg on days 2 through 5, to be taken on the 1 st and 3 rd weeks of the month Psoriasis [78, 79] A, R, E Inhibits the production of pro-inflammatory cytokines, such as IL-6, IL-8, and (TNF)-α perhaps by suppressing the transcription factors NF-κB or activator protein-1, and reduce neutrophil activity, [80] suppresses immunological events in interferon gamma-treated keratinocytes, including expression of MHC Class II, secretion of IL-1 alpha, and superantigen presenting ability [81, 82] R -150 mg orally twice daily for 1-7 weeks A -500 mg daily dose for 4 days with a gap of 10 days for 48 weeks E -1000 mg/day for 4 weeks Rosacea [83, 84] A Inhibits pro-inflammatory cytokines IL-1, -6, -8, and -10, GMCSF TNF-α, and LT-B4 [49, 66, [85] [86] [87] 500 mg on 3 days each week for 4 weeks SAPHO syndrome [88] [89] [90] [91] A Inhibits pro-inflammatory cytokines 500 mg on 6 successive days, followed by 500 mg twice a week [88] IL: Interleukin, TNF-α: Tumor necrosis factor-alpha, MMP: Matrix metalloproteinase, GMCSF: Granulocyte macrophage colony stimulating factor, LT: Leukotriene, SAPHO: Synovitis, acne, pustulosis, hyperostosis, and osteitis, OD: Once a day, BD: Twice a day, MHC: Major histocompatibility complex, A: Azithromycin, R: Roxithromycin, E: Erythromycin, C: Clarithromycin, NF: Nuclear factor
Levamisole
Levamisole is an anthelmintic agent with a wide range of immunomodulatory actions. It belongs to the class of imidazothiazole derivatives. It is water-soluble and gets rapidly absorbed from the gastrointestinal tract with peak blood levels achieved after 1.5-4 h. Metabolism of the drugs occurs mainly in liver and the plasma half-life is 16 h. Due to immunomodulatory properties, it has been widely used in various dermatological disorders. Usual dose of the drug is 150 mg/day for 2-4 days each week [ Table 9 ].
Side effects
All the above-discussed drugs have variety of side effects in the therapeutic dose range. The treating skin physician must be aware of commonly encountered side effects which can enable him or her to rationalize the treatment protocol and manage the side effects with due care [ Table 10 ].
Conclusions
The study aims to highlight the role of various antibiotic drugs in the management of noninfectious diseases of [92, 93] Immunosuppressive [89, 90] Antipruritic, inhibition of free radical generation by neutrophils [94] Topical -0.75% gel or cream, 1% gel, 2% gel Cutaneous metastatic Crohn's disease [95] Antibacterial action and possible anti-inflammatory 20 mg/kg Periorificial dermatitis [96] [97] [98] [99] Anti-inflammatory Immunosuppressive Inhibit free radical generation by neutrophils Topical -0.75-1% gel Oral -250 mg BD Rosacea [100] Anti-inflammatory mediated through inhibition of release of reactive oxygen species from neutrophils [101, 102] Topical -0.75% gel or 1% cream
Seborrheic dermatitis
Anti-inflammatory [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] Inhibition of free radical generation and oxidative tissue damage Topical -1% gel or 0.75% gel BD: Twice a day [108] Immunomodulatory effects through its capacity to alter the secretion of cytokines by human monocytes Clindamycin 300 mg BD PO+ Rifampicin 300 mg BD PO for 10 weeks Pruritus due to cholestasis [109] Induces Phase I, II, and III biotransformation enzymes and transporters such as CYP3A4, UGT1A1, SULTA1, and MRP2 [110] [111] [112] Enhances the metabolism of bilirubin and its breakdown products 300 mg/day Psoriasis [113] Immunosuppressive properties (both humoral and cellular immunity in vivo and in vitro) [114] [115] [116] 300 mg BD PO: Peroral, BD: Twice a day [117] Inhibits MMP-1 [118] ROS scavenging [119, 120] Inhibiting bacterial products that stimulate inflammation [121, 122] Confluent and reticulated papillomatosis [123] M Granulomatous diseases [124] D, M Inhibit T-cell proliferation and granuloma formation [125] D-200 mg/day, M-200 mg/day
Immunobullous diseases [126] [127] [128] T, M, D Inhibit MMP and mast cell activation [113] T-1500 mg/day, M-100 mg/day, D-100 mg/day Kaposi's sarcoma [129] Chemically modified tetracycline Inhibits MMP-2 and MMP-9 [130] Lichen planus [131] T, D Inhibition of the T-lymphocyte response [132] T -500 mg BD, D-100 mg BD Lupus miliaris disseminatus faciei [133] T, M Inhibits T-cell proliferation and granuloma formation [120] 100 mg/day Neutrophil disorders [134, 135] D, M Inhibit IL-8 and neutrophil activation [112] D -200 mg daily M -200-300 mg/day Contd... [136] T Inhibition of the T-lymphocyte response [127] 500 mg BD Prurigo pigmentosa [137, 138] D, M Inhibits the migration and/or function of neutrophils [112] Scavenging ROS
D -200 mg/day M -200 mg/day
Red scalp disease [139] L Inhibits matrix metalloproteinases Lymecycline -300 mg/ day Red scrotum syndrome [140] D Inhibits matrix metalloproteinases and thereby preventing tissue destruction 100 mg/day Rosacea [141] D, M Decreases ROS damage, including inhibiting neutrophils, direct scavenging of ROS, and inhibiting reactions that lead to ROS generation [112] Act on VEGF, iNOS, and NO and contribute to preventing excessive vascular dilatation and angiogenesis in rosacea [142] Improve epidermal hydration level [143] Inhibit granuloma formation in vitro [120] D Granulomatous disorders [148] [149] [150] HCQ, CQ Anti-inflammatory Stabilization of lysosomal membranes, inhibiting PGE synthesis, and possibly, other enzyme system [140] Inhibition of toll-like receptor 9 signal pathway-diminished antigen presentation and immune stimulation HCQ -6.5 mg/kg CQ -3.5-4 mg/kg Lichen planus [151] HCQ Anti-inflammatory
Decreasing the production of pro-inflammatory cytokines [140] Immunomodulatory
Reduced stimulation of autoreactive CD4+T cells [152] 200 mg BD Contd... [155] Immunomodulatory-Restoration of impaired T-cell function [156] 2.5 mg/kg/week (up to 150 mg/week)
Collagen vascular diseases [157, 158] Restoration of delayed hypersensitivity responses and improvement of impaired T-cell function and defective macrophage activity Rise in complement levels 150 mg/week for 3-24 months
Erythema multiforme [159, 160] Sequestration or elimination of persistent antigen
Increase IL-2 production by T lymphocytes 150 mg thrice weekly
Human immunodeficiency virus infection [161] Acts on macrophages and T-lymphocytes augmenting their functions such as phagocytosis, chemotaxis, adherence, intracellular killing, E-rosette formation, delayed skin hypersensitivity, and antigen-induced proliferation
Preferentially acts on T-helper-1 cells and upregulates IL-2, IL-12, and interferon-γ 2 mg/kg/day for 3 days each week for 24-52 weeks Leprosy [162] Immunostimulation-rapid bacterial clearance 150 mg thrice weekly Lichen planus [163] Decreases the levels of tumor necrosis factor-α, IL-6, and IL-8 150 mg thrice weekly Vitiligo [164] Inhibits the action of endogenous immunosuppressive factors such as
Inhibits increased B-cell activity -decrease immunoglobulin G, immunoglobulin M, and circulating immune complex levels [165] 150 mg on 2 consecutive days every week for periods varying from 4 to 48 months IL: Interleukin [154] 200 mg twice daily BD: Twice a day, PGE: Prostaglandin E, HCQ: Hydroxychloroquine, CQ: Chloroquine, MHC: Major histocompatibility complex skin and its appendages. In future, many more cutaneous diseases will be treated and managed with various antibiotics tapping their anti-inflammatory properties. We would like to highlight that in future, these antibiotics will be used albeit in continuous low-dose in various noninfectious dermatoses, thereby minimizing the incidence of side effects.
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What is new?
• Antibiotics refer to collective term for antibacterial, antiviral, and antiparasitic agents • Antibiotics have multifaceted actions besides killing the infectious organisms • Anti-inflammatory and immunomodulatory effects of antibiotics make them eligible to be used in various non-infectious conditions in dermatology • Anti-parasitic drugs are also used in dermatology for their anti-inflammatory and immunomodulatory properties. 
